{"id":33910,"date":"2020-09-10T15:42:14","date_gmt":"2020-09-10T13:42:14","guid":{"rendered":"https:\/\/wordpress-783423-2671269.cloudwaysapps.com\/?p=33910"},"modified":"2022-03-09T11:46:03","modified_gmt":"2022-03-09T10:46:03","slug":"dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2","status":"publish","type":"post","link":"https:\/\/dev.cometis.de\/en\/dermapharm-holding-se-signs-cooperation-agreement-with-biontech-on-the-production-of-a-covid-19-vaccine-2\/","title":{"rendered":"<span id=\"2020\" class=\"Postdate\">10 September 2020<\/span> | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE"},"content":{"rendered":"<p>[et_pb_section admin_label=&#8221;section&#8221;][et_pb_row admin_label=&#8221;Zeile&#8221; make_fullwidth=&#8221;off&#8221; use_custom_width=&#8221;off&#8221; width_unit=&#8221;on&#8221; use_custom_gutter=&#8221;off&#8221; custom_padding=&#8221;||0px|&#8221; padding_mobile=&#8221;off&#8221; allow_player_pause=&#8221;off&#8221; parallax=&#8221;off&#8221; parallax_method=&#8221;off&#8221; make_equal=&#8221;off&#8221; parallax_1=&#8221;off&#8221; parallax_method_1=&#8221;off&#8221; parallax_2=&#8221;off&#8221; parallax_method_2=&#8221;off&#8221; column_padding_mobile=&#8221;on&#8221;][et_pb_column type=&#8221;1_2&#8243;][et_pb_text admin_label=&#8221;Schaltfl\u00e4che %22zur\u00fcck zum Archiv%22&#8243; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<style>\n.zur\u00fcckbutton:before {<br \/>    display: inline-block;<br \/>    font-family: \"ETmodules\";<br \/>    content: \"4a\";<br \/>    color: #00225f;<br \/>    margin-right: 7px;<br \/>}<br \/>.zur\u00fcckbutton:hover:before {<br \/>    display: inline-block;<br \/>    font-family: \"ETmodules\";<br \/>    content: \"4a\";<br \/>    color: #d85710;<br \/>    margin-right: 7px;<br \/>}<br \/><\/style>\n<h1 style=\"text-align: justify;\">Ad hoc news<\/h1>\n<p><a class=\"zur\u00fcckbutton\" href=\"https:\/\/dev.cometis.de\/en\/publication-archive-dermapharm\">to the archive<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243;][et_pb_image admin_label=&#8221;Logo&#8221; src=&#8221;https:\/\/dev.cometis.de\/wp-content\/uploads\/2018\/08\/autodoc_Logo_Wei%C3%9F_2-7.png&#8221; show_in_lightbox=&#8221;off&#8221; url_new_window=&#8221;off&#8221; use_overlay=&#8221;off&#8221; animation=&#8221;off&#8221; sticky=&#8221;off&#8221; align=&#8221;right&#8221; force_fullwidth=&#8221;off&#8221; always_center_on_mobile=&#8221;on&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<br \/>\n[\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=&#8221;row&#8221;][et_pb_column type=&#8221;4_4&#8243;][et_pb_text admin_label=&#8221;Text&#8221; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221; saved_tabs=&#8221;all&#8221;]<\/p>\n<h1><strong><em>Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE<\/em><\/strong><\/h1>\n<p>Gr\u00fcnwald, September 10, 2020 \u2013 Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) and BioNTech SE, Mainz, Germany, have agreed that their production subsidiaries will cooperate on producing a COVID-19 vaccine. The production capacities at Dermapharm will be available to the cooperation partners BioNTech SE and Pfizer Inc. already when production of the vaccine begins.<\/p>\n<p><strong>Contacts<\/strong><br \/>\nInvestor Relations &amp;<br \/>\nCorporate Communications<br \/>\nBritta Hamberger<br \/>\nPhone: +49 (0)89 \u2013 64186-233<br \/>\nFax: +49 (0)89 \u2013 64186-165<br \/>\nE-mail: <a href=\"mailto:ir@dermapharm.com\">ir@dermapharm.com<\/a><\/p>\n<p><strong>cometis AG <\/strong><br \/>\nClaudius Krause<br \/>\nPhone: +49 (0)611 \u2013 205855-28<br \/>\nFax: +49 (0)611 \u2013 205855-66<br \/>\nE-mail: <a href=\"mailto:ir@dermapharm.com\">ir@dermapharm.com <\/a><\/p>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;Schaltfl\u00e4che %22Beitrag als PDF%22&#8243; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<div class=\"leseprobe-archiv\"><a title=\"Beitrag als PDF\" href=\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2020\/09\/EN_20200910_Ad-hoc_Biontech-FINAL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Read as PDF<\/a><\/div>\n<style> .leseprobe-archiv {color: #00225f !important; border-color: #00225f; position: relative; padding: 0.3em 1em; border: 1px solid; -webkit-border-radius: 3px; -moz-border-radius: 3px; border-radius: 3px; -webkit-transition: all 0.2s; -moz-transition: all 0.2s; transition: all 0.2s; padding:10px; width: 19%; text-align: center; margin-right: 10px; float:left;} .leseprobe-archiv:hover {background-color: #eee; border-color: #ffffff; cursor: pointer;}<\/style>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ad hoc news to the archive Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE Gr\u00fcnwald, September 10, 2020 \u2013 Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) and BioNTech SE, Mainz, Germany, have agreed that their production subsidiaries will cooperate on producing a COVID-19 vaccine. The production capacities at Dermapharm will be available [&hellip;]<\/p>\n","protected":false},"author":24813,"featured_media":54374,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[325,448],"tags":[482],"class_list":["post-33910","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dermapharm-ad-hoc-news","category-news-en","tag-482"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE - cometis AG<\/title>\n<meta name=\"description\" content=\"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE - cometis AG\" \/>\n<meta property=\"og:description\" content=\"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/\" \/>\n<meta property=\"og:site_name\" content=\"cometis AG\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-10T13:42:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-09T10:46:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\" \/>\n\t<meta property=\"og:image:width\" content=\"172\" \/>\n\t<meta property=\"og:image:height\" content=\"174\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Assistenz cometis AG\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Assistenz cometis AG\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/\"},\"author\":{\"name\":\"Assistenz cometis AG\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6\"},\"headline\":\"10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE\",\"datePublished\":\"2020-09-10T13:42:14+00:00\",\"dateModified\":\"2022-03-09T10:46:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/\"},\"wordCount\":356,\"publisher\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"keywords\":[\"2020\"],\"articleSection\":[\"Dermapharm Ad-Hoc News\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/\",\"url\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/\",\"name\":\"10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE - cometis AG\",\"isPartOf\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"datePublished\":\"2020-09-10T13:42:14+00:00\",\"dateModified\":\"2022-03-09T10:46:03+00:00\",\"description\":\"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#primaryimage\",\"url\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"contentUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg\",\"width\":172,\"height\":174,\"caption\":\"Icon Newsroom_news\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#website\",\"url\":\"https:\/\/dev.cometis.de\/de\/\",\"name\":\"cometis AG\",\"description\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"publisher\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dev.cometis.de\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#organization\",\"name\":\"cometis AG\",\"alternateName\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"url\":\"https:\/\/dev.cometis.de\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png\",\"contentUrl\":\"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png\",\"width\":171,\"height\":31,\"caption\":\"cometis AG\"},\"image\":{\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6\",\"name\":\"Assistenz cometis AG\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g\",\"caption\":\"Assistenz cometis AG\"},\"url\":\"https:\/\/dev.cometis.de\/en\/author\/assistenz-cometis-ag\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE - cometis AG","description":"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE - cometis AG","og_description":"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.","og_url":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/","og_site_name":"cometis AG","article_published_time":"2020-09-10T13:42:14+00:00","article_modified_time":"2022-03-09T10:46:03+00:00","og_image":[{"width":172,"height":174,"url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","type":"image\/png"}],"author":"Assistenz cometis AG","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Assistenz cometis AG","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#article","isPartOf":{"@id":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/"},"author":{"name":"Assistenz cometis AG","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6"},"headline":"10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE","datePublished":"2020-09-10T13:42:14+00:00","dateModified":"2022-03-09T10:46:03+00:00","mainEntityOfPage":{"@id":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/"},"wordCount":356,"publisher":{"@id":"https:\/\/dev.cometis.de\/de\/#organization"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","keywords":["2020"],"articleSection":["Dermapharm Ad-Hoc News","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/","url":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/","name":"10 September 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE - cometis AG","isPartOf":{"@id":"https:\/\/dev.cometis.de\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#primaryimage"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#primaryimage"},"thumbnailUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","datePublished":"2020-09-10T13:42:14+00:00","dateModified":"2022-03-09T10:46:03+00:00","description":"Die Dermapharm Holding SE (\u201eDermapharm\u201c), ein f\u00fchrender Hersteller von patentfreien Markenarzneimitteln f\u00fcr ausgew\u00e4hlte Therapiegebiete wird ab dem vierten Quartal 2020 das Mainzer Unternehmen BioNTech SE mit Impfstoff zur Bek\u00e4mpfung des COVID-19-Virus beliefern.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/de\/09-september-2020-dermapharm-holding-se-schliesst-kooperationsvereinbarung-mit-biontech-zur-produktion-eines-covid-19-impfstoffs\/#primaryimage","url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","contentUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/03\/icon_newsroom.svg","width":172,"height":174,"caption":"Icon Newsroom_news"},{"@type":"WebSite","@id":"https:\/\/dev.cometis.de\/de\/#website","url":"https:\/\/dev.cometis.de\/de\/","name":"cometis AG","description":"Deutschlands f\u00fchrende Investor Relations Agentur","publisher":{"@id":"https:\/\/dev.cometis.de\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dev.cometis.de\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/dev.cometis.de\/de\/#organization","name":"cometis AG","alternateName":"Deutschlands f\u00fchrende Investor Relations Agentur","url":"https:\/\/dev.cometis.de\/de\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/","url":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png","contentUrl":"https:\/\/dev.cometis.de\/wp-content\/uploads\/2022\/01\/Cometis-Mobile-Logo-1.png","width":171,"height":31,"caption":"cometis AG"},"image":{"@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/6790c5b0cf28f5e8c09401346770e6f6","name":"Assistenz cometis AG","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dev.cometis.de\/de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d9db77bcddbfa0c99848135c21ae5b93?s=96&d=mm&r=g","caption":"Assistenz cometis AG"},"url":"https:\/\/dev.cometis.de\/en\/author\/assistenz-cometis-ag\/"}]}},"_links":{"self":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts\/33910","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/users\/24813"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/comments?post=33910"}],"version-history":[{"count":0,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/posts\/33910\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/media\/54374"}],"wp:attachment":[{"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/media?parent=33910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/categories?post=33910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dev.cometis.de\/en\/wp-json\/wp\/v2\/tags?post=33910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}